Search clinical trials for: Monoclonal+antibody

Total 3489 results

Humanigen, Inc.

Completed

Study of Lenzilumab in Previously Treated Patients With Chronic Myelomonocytic Leukemia (CMML)

Chronic Myelomonocytic Leukemia (CMML)

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

Recurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Rectal Adenocarcinoma | Colon Adenocarcinoma | ERBB2 Gene Amplification | Stage III Colon Cancer AJCC v7 | Stage III Rectal Cancer AJCC v7 | Stage IIIA Colon Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Colon Cancer AJCC v7 | Stage... and other conditions

United States, Puerto Rico
University of Arizona
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer

Lymphoma | Myelodysplastic Syndromes | Leukemia | Chronic Myeloproliferative Disorders | Unspecified Adult Solid Tumor, Protocol Specific | Multiple Myeloma and Plasma Cell Neoplasm | Precancerous/Nonmalignant Condition

United States
Beijing VDJBio Co., LTD.

Completed

Clinical Study of Single Dose IL-6R mAb Injection in RA Patients

Rheumatoid Arthritis

China
Shenyang Sunshine Pharmaceutical Co., LTD.

Completed

A Trial With Humanized TNFα Monoclonal Antibody Injection by Single Dose and Dose Escalation in Healthy Subjects

Rheumatoid Arthritis

China
National Cancer Institute (NCI)

Completed

Chemotherapy and Progenitor Cell Transplantation to Treat Inflammatory Breast Cancer

Neoplasm Metastasis | Breast Neoplasm

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer

Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | HER2 Positive Breast Carcinoma

United States
SWISS BIOPHARMA MED GmbH

Completed

Phase 0/1 Local Application of the Monoclonal Antibody (Mab) sB24M in Patients With Purulent Pyoderma

Pyoderma | Pyoderma Gangrenosum | Pyoderma Vegetans | Pyoderma Gangrenosum Surrounding Surgical Stoma

Belarus, Latvia
Keymed Biosciences Co.Ltd

Recruiting

The Study of CM310 in Patients With Atopic Dermatitis

Moderate-to-severe Atopic Dermatitis

China
Bio-Thera Solutions

Active, not recruiting

Assessment of Safety and Preliminary Efficacy With BAT6026 in Solid Tumor Patients in China

Advanced Solid Tumors

China
University of Arizona
National Cancer Institute (NCI)

Completed

Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma

Head and Neck Cancer | Recurrent Head and Neck Squamous Cell Carcinoma | Oropharyngeal Cancer | HNSCC | Recurrent Oropharyngeal Squamous Cell Carcinoma | Stage IV Squamous Cell Carcinoma of the Lip and Oral Cavity | Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma | Stage IVA Nasal Cavity and... and other conditions

United States
Janssen Research & Development, LLC

Completed

A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

United States
The First Affiliated Hospital with Nanjing Medical...

Recruiting

A Study of Tislelizumab Combined With Radiotherapy as the Second-line Treatment of Advanced Biliary Malignant Tumors

Cholangiocarcinoma

China
Biotech Pharmaceutical Co., Ltd.

Terminated

Tolerability, Safety and Pharmacokinetic Study of Humanized Anti-CD6 Monoclonal Antibody Injection in Chinese Psoriasis

Psoriasis

China
Rockefeller University

Completed

3BNC117-LS First-in-Human Phase 1 Study

Human Immunodeficiency Virus

United States
Lee's Pharmaceutical Limited

Unknown

TAB014(Drug Code) in Wet( Neovascular)Age-related Macular Degeneration(AMD) Subjects

AMD

China
Probiomed S.A. de C.V.

Unknown

TREatment of degeNerative and Neoplastic Diseases With Rituximab (TREND)

Diffuse Large B Cell Lymphoma

Mexico
Shanghai Henlius Biotech

Not yet recruiting

Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor or Lymphoma

Solid Tumor, Adult Lymphoma
Weill Medical College of Cornell University

Completed

177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors

Kidney Cancer | Breast Cancer | Head and Neck Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Ovarian Cancer | Non-small Cell Lung Cancer | Gliomas

United States
Abramson Cancer Center of the University of Pennsylvania

Completed

Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma

Pleural Malignant Mesothelioma

United States
Henlix, Inc

Terminated

A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors

Solid Tumor, Adult

Taiwan
Implicit Bioscience
Royal Brisbane and Women's Hospital

Completed

Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease

Motor Neuron Disease | Amyotrophic Lateral Sclerosis

Australia
Queen Mary University of London
Gilead Sciences

Unknown

Monoclonal Antibodies in Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) (MARALL) (MARALL)

Recurrent or Refractory B Cell Acute Lymphoblastic Leukaemia

United Kingdom
Northwestern University
GlaxoSmithKline; National Comprehensive Cancer Network

Active, not recruiting

Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia

Stage I Chronic Lymphocytic Leukemia | Stage II Chronic Lymphocytic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia

United States, Sweden
National Cancer Institute (NCI)

Terminated

Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic Kidney Cancer

Renal Cell Carcinoma | Stage III Renal Cell Cancer | Stage IV Renal Cell Cancer | Recurrent Renal Cell Cancer

United States
University of Southern California
National Cancer Institute (NCI)

Terminated

CMP-001 and INCAGN01949 for Patients With Stage IV Pancreatic Cancer and Other Cancers Except Melanoma

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm

United States
Lanzhou Institute of Biological Products Co., Ltd

Recruiting

Phase Ⅰ Clinical Study of Anti-CD52 Monoclonal Antibody in NHL and T-PLL

Lymphoma, Non-Hodgkin | Lymphoma, T-Cell

China
Jiangsu Simcere Pharmaceutical Co., Ltd.

Recruiting

A Phase I Trial of SIM1811-03 in Subjects With Advanced Solid Tumors and Cutaneous T-cell Lymphoma

Advanced Solid Tumor | Cutaneous T-cell Lymphoma (CTCL)

United States
Implicit Bioscience

Withdrawn

A Phase 2 Study of IC14 in Acute Respiratory Distress Syndrome

Acute Respiratory Distress Syndrome
National Institute of Dental and Craniofacial Research...

Terminated

Pilot Study of Raptiva to Treat Sjogren's Syndrome

Sjogren's Syndrome

United States
National Cancer Institute (NCI)

Completed

Apolizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Stage III Small Lymphocytic Lymphoma | Stage IV Small Lymphocytic Lymphoma | Noncontiguous Stage II Small Lymphocytic Lymphoma

United States
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Small Lymphocytic... and other conditions

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer

Prostate Cancer

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia

Lymphoma | Leukemia

United States
Shanghai Henlius Biotech

Completed

A Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of HLX26 Monoclonal Antibody Injection in Patients With Solid Tumor or Lymphoma

Lymphoma | Solid Tumor, Adult

China
FibroGen

Completed

Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis

United States
Cancer Institute and Hospital, Chinese Academy...

Unknown

GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma

Lymphoma | Tumor, Solid

China
HuniLife Biotechnology, Inc.

Recruiting

A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HuL001

Idiopathic Pulmonary Fibrosis

Taiwan
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin Pharma, Inc.

Terminated

Phase 1/2 Study of Anti GM-2 Monoclonal Antibody To Treat Multiple Myeloma

Multiple Myeloma

United States
Henlix, Inc

Unknown

Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors

Solid Tumor

Taiwan
Biocad

Active, not recruiting

Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (ELEFTA)

Axial Spondyloarthritis

Russian Federation
David Rizzieri, MD

Completed

Safety Trial of NK DLI From 6/6 HLA Matched Family Member Following Nonmyeloablative ASCT

Lymphoma

United States
Grupo Espanol Multidisciplinario del Cancer Digestivo

Active, not recruiting

Observational Study to Evaluate the Use of Targeted Therapies in Metastatic Colorectal Cancer

Metastatic Colon Cancer

Spain
Beijing VDJBio Co., LTD.

Recruiting

A Study of Anti-IL-6R mAb Injection in Patients With iMCD

Idiopathic Multicentric Castleman's Disease

China
George W. Sledge Jr.
National Cancer Institute (NCI)

Completed

4-1BB Agonist Monoclonal Antibody PF-05082566 With Trastuzumab Emtansine or Trastuzumab in Treating Patients With Advanced HER2-Positive Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | HER2 Positive Breast Carcinoma | Stage III Breast Cancer

United States
Shanghai Henlius Biotech

Suspended

Evaluate the Efficacy, Safety and Tolerability of HLX26 and Serplulimab in Patients With mCRC

Colorectal Cancer Metastatic

China
Garden State Cancer Center at the Center for Molecular...
National Cancer Institute (NCI)

Unknown

Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer

Lung Cancer

United States
Garden State Cancer Center at the Center for Molecular...
National Cancer Institute (NCI)

Unknown

Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer

Lung Cancer

United States
Northwestern University
National Cancer Institute (NCI); Pfizer

Terminated

Palbociclib in Treating Patients With Metastatic HER-2 Positive Breast Cancer With Brain Metastasis

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Estrogen Receptor Negative | HER2/Neu Negative | HER2/Neu Positive | Progesterone Receptor Negative | Breast Carcinoma Metastatic in the Brain

United States
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Adenocarcinoma | Stage III Uterine Corpus Cancer AJCC v7 | Stage IV Uterine Corpus Cancer AJCC v7 | ERBB2 Gene Amplification

United States

Search clinical trials for: Monoclonal+antibody

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations